A license agreement to utilise the novel ‘payload’ (drug-linker) technology developed by Nerviano Medical Sciences has been signed with Oxford BioTherapeutics: the company will use the platform developed in Italy to expand the of development its Antibody Drug Conjugates (ADC) portfolio for the treatment of cancer. The deal gives OBT access to a new payload technology based on a next-generation duocarmycin analogue. Nerviano will receive undisclosed fees, development linked milestones and royalties for granting OBT access to its technology.